{
    "clinical_study": {
        "@rank": "58921", 
        "brief_summary": {
            "textblock": "To provide oral ganciclovir to patients who require maintenance for control of\n      cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for\n      long-term administration of intravenous drugs."
        }, 
        "brief_title": "An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access", 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of\n      enrollment will receive 2 months of study drug and undergo follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  Stable CMV retinitis.\n\n          -  Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days.\n\n          -  No permanent central IV catheter at present.\n\n          -  Had a permanent central IV catheter removed two or more times within the past 6\n             months due to catheter infection or thrombosis.\n\n          -  Consent of guardian if less than legal age of consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Require continuation of concomitant medications precluded by this protocol.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Intravitreal anti-CMV treatment.\n\n          -  Any other concomitant medications precluded by the protocol.\n\n        Patients with the following prior condition are excluded:\n\n        History of hypersensitivity to acyclovir or ganciclovir."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002135", 
            "org_study_id": "037C", 
            "secondary_id": "GANS2224"
        }, 
        "intervention": {
            "intervention_name": "Ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "Retinitis", 
            "Ganciclovir", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94303"
                }, 
                "name": "Roche Global Development - Palo Alto"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "PMID": "7639972", 
                "citation": "Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS. 1995 May;9(5):471-7."
            }, 
            {
                "PMID": "7637721", 
                "citation": "Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995 Sep 7;333(10):615-20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002135"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1995"
    }, 
    "geocoordinates": {
        "Roche Global Development - Palo Alto": "37.442 -122.143"
    }
}